Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Botanix Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
Biocurious: FDA approval remains the Holy Grail for ASX life science stocks
News
Closing Bell: ASX dips further as Macquarie downgrade sends coal stocks tumbling
Health & Biotech
Botanix climbs into ASX 300 club, strengthening its global dermatology ambitions
Long Shortz
Long Shortz with Botanix Pharmaceuticals: a new major milestone
Health & Biotech
Health Check: Poly oh no! Polynovo shares resume slide as CEO goes
Health & Biotech
Biocurious: With Mayne Pharmaceuticals under takeover offer, who’s next?
Health & Biotech
Health Check: Clinical trials don’t sleigh down for the silly season
Health & Biotech
Biocurious: No sweat as Botanix tackles the world’s third-biggest skin disorder
Health & Biotech
Health Check: Which biotech boards are at risk of a ‘second strike’?
Health & Biotech
Alive and Kicking: No sweat as Botanix readies for US launch of its hyperhidrosis treatment
Health & Biotech
The ASX biotechs with secured FDA clearances in 2024, and others looking likely
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise as M&A activity heats up
Health & Biotech
ASX Health Stocks: Control Bionics surges over 50pc after TGA approval of DROVE wheelchair
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
Weed Week: MDMA for PTSD hits roadblock with FDA; and recent ASX cannabis stock winners
Health & Biotech
Top ASX biotechs catching the eye of analysts and fund managers in 2024 – Part 2
Health & Biotech
